Our findings highlight the feasibility of using RT-qPCR, instead of IHC, for the routine assessment of IGF2BP3 in order to assist in the selection of melanoma patients with a higher risk of developing distant metastasis or dying from melanoma. The gene discussed is IGF2BP3; the disease is melanoma.